Summit Trail Advisors LLC Buys 71 Shares of Becton, Dickinson and Company (NYSE:BDX)

Summit Trail Advisors LLC increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,422 shares of the medical instruments supplier’s stock after buying an additional 71 shares during the period. Summit Trail Advisors LLC’s holdings in Becton, Dickinson and Company were worth $332,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of BDX. Gryphon Financial Partners LLC bought a new position in shares of Becton, Dickinson and Company during the fourth quarter worth approximately $211,000. Congress Wealth Management LLC DE increased its position in Becton, Dickinson and Company by 7.9% during the 4th quarter. Congress Wealth Management LLC DE now owns 1,809 shares of the medical instruments supplier’s stock worth $441,000 after buying an additional 133 shares during the period. Hilltop Holdings Inc. acquired a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth $472,000. Peak Asset Management LLC boosted its position in shares of Becton, Dickinson and Company by 4.7% in the fourth quarter. Peak Asset Management LLC now owns 46,842 shares of the medical instruments supplier’s stock valued at $11,421,000 after acquiring an additional 2,122 shares during the period. Finally, Proquility Private Wealth Partners LLC acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at about $205,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $234.70 on Tuesday. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. The stock has a market cap of $67.83 billion, a PE ratio of 51.70, a P/E/G ratio of 1.91 and a beta of 0.42. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $269.52. The business’s 50-day moving average price is $235.68 and its two-hundred day moving average price is $235.52.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The business had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. During the same period in the prior year, the company earned $2.96 EPS. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. As a group, analysts expect that Becton, Dickinson and Company will post 13.1 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 1.62%. The ex-dividend date is Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Analysts Set New Price Targets

Several brokerages have weighed in on BDX. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. The Goldman Sachs Group initiated coverage on Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 price target for the company. Stifel Nicolaus raised their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Raymond James dropped their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Finally, Evercore ISI reduced their target price on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $279.50.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.